公开(公告)号：US09938288B1

公开(公告)日：2018-04-10

申请号：US15814105

申请日：2017-11-15

Applicant: President and Fellows of Harvard College ,  Eisai R&D Management Co., Ltd.

Inventor： Yoshito Kishi ,  Kazunobu Kira ,  Ken Ito

IPC: C07D498/22 ,  A61K31/357 ,  C07D493/22 ,  A61K39/395

CPC classification number: C07D493/22 ,  A61K31/357 ,  A61K39/3955 ,  A61K2300/00

Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.

公开(公告)号：US20230406863A1

公开(公告)日：2023-12-21

申请号：US18339227

申请日：2023-06-21

Applicant: President and Fellows of Harvard College ,  Eisai R&D Management Co., LTD.

Inventor： Yoshito Kishi ,  Kazunobu Kira ,  Ken Ito

IPC: C07D493/22 ,  A61P35/00 ,  A61K31/357 ,  A61K39/395 ,  C07K16/28

CPC classification number: C07D493/22 ,  A61P35/00 ,  A61K31/357 ,  A61K39/3955 ,  C07K16/2818 ,  C07K16/2863 ,  A61K2039/505

Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.

公开(公告)号：US11814398B2

公开(公告)日：2023-11-14

申请号：US17808418

申请日：2022-06-23

Applicant: President and Fellows of Harvard College ,  Eisai R&D Management Co., LTD.

Inventor： Yoshito Kishi ,  Kazunobu Kira ,  Ken Ito

IPC: C07D493/22 ,  A61P35/04

CPC classification number: C07D493/22 ,  A61P35/04

Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.

公开(公告)号：US20230016686A1

公开(公告)日：2023-01-19

申请号：US17808418

申请日：2022-06-23

Applicant: President and Fellows of Harvard College ,  Eisai R&D Management Co., LTD.

Inventor： Yoshito Kishi ,  Kazunobu Kira ,  Ken Ito

IPC: C07D493/22 ,  A61P35/04

Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.

公开(公告)号：US10954249B2

公开(公告)日：2021-03-23

申请号：US16500924

申请日：2018-04-03

Applicant: President and Fellows of Harvard College ,  Eisai R&D Management Co., LTD.

Inventor： Yoshito Kishi ,  Kazunobu Kira ,  Ken Ito

IPC: C07D493/22 ,  A61K39/395 ,  A61K31/357 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.

公开(公告)号：US10745387B2

公开(公告)日：2020-08-18

申请号：US15529798

申请日：2016-11-17

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Gregg F. Keaney ,  John Wang ,  Baudouin Gerard ,  Kenzo Arai ,  Xiang Liu ,  Guo Zhu Zheng ,  Kazunobu Kira ,  Parcharee Tivitmahaisoon ,  Sudeep Prajapati ,  Nicholas C. Gearhart ,  Yoshihiko Kotake ,  Satoshi Nagao ,  Regina Mikie Kanada Sonobe ,  Masayuki Miyano ,  Norio Murai ,  Silvia Buonamici ,  Lihua Yu ,  Eunice Sun Park ,  Betty Chan ,  Peter G. Smith ,  Michael P. Thomas ,  Ermira Pazolli ,  Kian Huat Lim ,  Atsushi Endo ,  Arani Chanda

IPC: A61K31/496 ,  C07D295/182 ,  C07D405/14 ,  C07D405/06 ,  A61P35/02

Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.